Table 4 Prognostic factors from series considering unselected populations and related survivals
From: Surgical treatment of liver metastases of gastric cancer: state of the art
| Author year | Number | Timing | MST (months) | 1-, 3-, 5-year survival rates | Prognostic factors |
|---|---|---|---|---|---|
| 2008 [37] | 58 | Synchronous + metachronous | Overall: 16 | No hepatic resection: 29.4%; 0%; 0% | |
| Hepatic resection RFA: 75.3%; 31.7%; 20.8% | Ro resection | ||||
| 2009 [50] | 72 | Synchronous | NA | No hepatic resection: 36.4%; 0%; 0% | |
| Hepatic resection (HAIC): 80%; 60%; 60% | H; P; R0 resection | ||||
| 2009 [51] | 73 | Metachronous | Overall: 7 | ||
| BST: 5 | |||||
| Chemotherapy: 12 | |||||
| Hepatic resection: 23 | BST: 22%; 2%; 0% | ||||
| Chemotherapy: 45%; 6%; 0% | |||||
| Hepatic resection; 81%; 20%; 20% | T; N; G of primary | ||||
| R0 resection | |||||
| 2009 [52] | 73 | Synchronous | Stage of primary; H | ||
| Extrahepatic disease; treatment of mets | |||||
| 2010 [49] | Synchronous + metachronous | Overall: 16 | |||
| Hepatic resection: 31.2 | No hepatic resection: 53.2%; 4.2%; 0% | ||||
| Hepatic resection: 82.3%; 46.4%; 37.1% |